CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysis Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score

Guideline26 August 2017

JOURNAL:European Heart Journal Article Link

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery

M.Valgimigli, H. Bueno, R. A. Byrne et al Keywords: Myocardial DiseaseAcute Coronary Syndromes (ACS)Cardiovascular Pharmacology and Pharmacotherapy

Full Text PDF